No difference in radiologic outcomes for natalizumab patients on extended interval dosing compared with standard interval dosing in MS PATHS

被引：0
|
作者：
Ryerson, Lana Zhovtis [1 ]
Naismith, Robert T. [2 ]
Krupp, Lauren B. [1 ]
Charvet, Leigh [1 ]
Liao, Shirley [3 ]
Fisher, Elizabeth [3 ]
De Moor, Carl [3 ]
Williams, James R. [3 ]
Licata, Stephanie [3 ]
Campbell, Nolan [3 ]
机构：
[1] NYU, Dept Neurol, NYU Langone Hlth, New York, NY 10003 USA
[2] Washington Univ, Dept Neurol, St Louis, MO 14263 USA
[3] Biogen, Cambridge, MA USA
来源：
NEUROLOGY | 2021年 / 96卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1964
引用
下载
收藏
页数：3
相关论文
共 50 条
  • [21] Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
    Ryerson, Lana Zhovtis
    Foley, John
    Chang, Ih
    Kister, Ilya
    Cutter, Gary
    Metzger, Ryan R.
    Goldberg, Judith D.
    Li, Xiaochun
    Riddle, Evan
    Smirnakis, Karen
    Kasliwal, Rachna
    Ren, Zheng
    Hotermans, Christophe
    Ho, Pei-Ran
    Campbell, Nolan
    NEUROLOGY, 2019, 93 (15) : E1452 - E1462
  • [22] Effectiveness of natalizumab extended interval dosing in multiple sclerosis patients
    Petrzalka, M.
    Meluzinova, E.
    Mojzisova, H.
    Libertinova, J.
    Rockova, P.
    Nema, E.
    Elisak, M.
    Marusic, P.
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2020, 83 (01) : 79 - 83
  • [23] Treatment adherence is more crucial in extended interval dosing than standard dosing among natalizumab users
    Seferoglu, Meral
    Sivaci, Ali Ozhan
    Cinar, Bilge Piri
    Tunc, Abdulkadir
    Bunul, Sena Destan
    Ethemoglu, Ozlem
    Tekan, Ulgen Yalaz
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 975 - 976
  • [24] Progressive Multifocal Leukoencephalopathy with Natalizumab Extended or Standard Interval Dosing in US and ROW
    Dsilva, L.
    McCarthy, K.
    Lyons, J.
    Cabigas, B.
    Campbell, N.
    Kong, G.
    Chin, W.
    Adams, B.
    Kuhelj, R.
    Singhal, P.
    Smirnakis, K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 459 - 459
  • [25] No Difference in Disability Progression of MS Patients Treated with Extended Interval vs. Standard Interval Natalizumab
    Fallon, Julia
    Kister, Ilya
    Ryerson, Lana Zhovtis
    NEUROLOGY, 2016, 86
  • [26] Extended-interval dosing of natalizumab in NOVA Reply
    Foley, John F.
    Campbell, Nolan
    Kong, George
    LANCET NEUROLOGY, 2023, 22 (03): : 200 - 201
  • [27] Extended interval dosing of natalizumab: More evidence in support
    Toljan, Karlo
    Conway, Devon S.
    NEUROTHERAPEUTICS, 2024, 21 (03)
  • [28] Natalizumab Extended Interval Dosing: Real Life Experience
    Jacques, Francois
    Lebel, Marie-Christine
    Timite, Halilou
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1016 - 1017
  • [29] Safety of extended interval dosing of Natalizumab in clinical practice
    Pastor, S.
    Fernandez-Fournier, M.
    Sastre Real, M.
    Perez Lucas, J.
    Puertas Munoz, I.
    Tallon, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 335 - 336
  • [30] Pharmacodynamics and pharmacokinetics of natalizumab administered at extended interval dosing
    Ryerson, L. Zhovtis
    Zuniga-Estrada, G.
    Jacob, A.
    Bacon, T.
    Pandey, K.
    Mohn, J.
    Kister, I.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 917 - 918
12345